Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today reported that it will host a Research & Development Day to highlight advances in the Company’s pipeline, in New York City on March 1, 2017 from 12:00pm to 2:30pm ET.
The meeting will feature presentations by key opinion leaders Yoav Golan, MD, MS, FIDSA (Tufts Medical Center) and Thomas M. Hooton, MD (University of Miami School of Medicine), who will discuss the current treatment landscape for MDR gram-negative infections and novel treatments under development. Both experts will be available to answer questions.
Achaogen will provide an overview of its lead product candidate, plazomicin, which is being developed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Management will also outline notable progress on the research and preclinical pipeline, including an overview of a new program that is planned to commence human clinical trials in 2017, and advances with their antibody discovery platform.
Yoav Golan, MD, MS, FIDSA is currently an attending physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center and Associate Professor of Medicine at Tufts University School of Medicine. His fields of professional expertise include hospital-acquired infections, antibiotic resistance and its impact on patient outcomes and pharmacoeconomics. Over the past 10 years, Dr. Golan has been involved in the pre-clinical and clinical development of several antibiotics, including Cubicin, Dificid and Teflaro. Dr. Golan has a comprehensive understanding of clinical research methodologies and, as a clinician and researcher, he is familiar first-hand with current unmet medical needs.
Thomas M. Hooton, MD is a Professor of Clinical Medicine at University of Miami School of Medicine, and Medical Director for Infection Control and Occupational Health at the University of Miami Health System. He has devoted his 30-year career to clinical care and research in infectious diseases. Considered one of the nation’s leading experts in the epidemiology, pathogenesis, and treatment of urinary tract infection (UTI), Dr. Hooton has chaired and served on several committees of the Infectious Diseases Society of America that publish guidelines on screening and treating asymptomatic bacteriuria, catheter-associated and uncomplicated urinary tract infection, and antimicrobial stewardship. Dr. Hooton received his medical degree from the University of Texas Southwestern Medical School in Dallas.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve attendance, email or contact LifeSci Advisors, LLC at [email protected]. A live and archived webcast of the event, with slides, will be available at http://lifesci.rampard.com/20170301/reg.jsp and on the Investors section of the Company’s website at www.achaogen.com.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen's lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen's plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen's gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
Investor Contact: Hans Vitzthum 212.915.2568 [email protected] Media Contact: Denise Powell 510.703.9491 [email protected]
